

Mass spectrometry analysis of non-protein amino acid misincorporation and proteomic changes in neurotoxicity-related cellular pathways

Joel Ricky Steele

Bachelors Medical Science (Hons)

Submitted in fulfilment of the requirements for the degree of Doctor
of Philosophy from:

Faculty of Science,

University of Technology Sydney

2022

Certificate of Original Authorship

I, Joel Ricky Steele declare that this thesis, is submitted in fulfilment of the requirements for the award of Doctor of Philosophy, in the Faculty of Science at the University of Technology Sydney.

This thesis is wholly my own work unless otherwise referenced or acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

This document has not been submitted for qualifications at any other academic institution.

This research is supported by the Australian Government Research Training Program, a UTS Excellence Scholarship and a Jumbunna Indigenous House of Learning Scholarship.

Signature:

Production Note:
Signature removed prior to publication.

Date: 14th May 2022

Acknowledgements

The completion of a PhD thesis is a monumental task, and it takes many hands for this to be possible from those that came before us and those that assisted during the process, I would like to recognise all of those that made this possible. Jumbunna, I would like to acknowledge all of those that came before me, my brothers & sisters, my Ancestors, and the land we are on. I would like to thank the Aurora Education Foundation for providing me opportunities that have propelled my career down a path that I could never have dreamed possible. The many teachers that encouraged me to get where I am and fanned the flames for my love of science. Nicole Pitt, Margret St Hill and Beryl Chisholm.

My proteomics story began with a lecturer that called out some then shameful political figures and shone a light on the world of proteomics. Sitting in the lecture theatre I remember hearing about how amazing proteins were and that they were the machines of the cell and so much more, the shock that this field of research had not been covered in the previous two years of university or at high school was astounding. This field of research had the promise to change the world. I still think this rings true as we move towards research that characterises true phenotypes of disease. It was by happen chance that I saw Matthew Padula at the woollies at central, it was there that I asked him to allow me to perform research in his laboratory, this was the point where I can say my goals became clear on what sort of career I wanted to have and how I could make an impact on the world. I thank him for the opportunities and mentorship that he has provided me over the past eight years, the editing of my work, the many well worded references and everything else that goes along with mentoring a student. Thank you for exposing me to Lorne and welcoming me to the world of proteomics, I wish you the best in all things.

Beginning my research, I was taken under the wing of Dr Kate Harvey, who till this day has been one of the most kind-hearted, patient, and intelligent people I know. I would like to thank you for everything you have done for me, especially performing all those growth curves for me so I didn't have to manually figure out incubation times. Your friendship has been one of the best things in my life. Thank you also to Marina Harvey for the many vodka nights and the good life and academic advice.

I would like to thank all the members of the UTS Proteomics Facility over the past eight years, you have all been great to work beside and thank you all for your guidance/help. Furthermore, I would also like to thank Steven Djordjevic for his guidance as well as all the members of his lab over the years. This includes Ronnie, Jacqui, Iain, Mars, Cam, Max and many others.

Ken Rodgers, I would like to thank you for your mentorship and the opportunities you have afforded me, you took a chance on supervising me. You have been a great friend, helping me grow to the scientist I am and more importantly put up with my hairbrained ideas (and poor writing). Similarly, I would like to thank the many members of the Rodger laboratory over the years, beginning with Kate and Brendan. Thank you, Jake, for the help and friendship over the years, I wish you nothing but the best.

Thanks to all the undergrad friends who helped me get here, especially Dr. Angus Clulow for his Gus-Pass sessions, Dr. Fennel, Ante M and all those others for their care and friendship. Thank you to the close members of the office/labs, my fellow PhD-sufferers including Amber and Andrew.

Thank you, Dr Carly Italiano, for being simply amazing, your friendship honestly got me through some of the lowest points of my life and you have helped me in so many ways. I wish you the world and every happiness.

Thank you to Dr Ralf Schittenhelm for hiring me into my dream job and providing me mentorship over the past year, you and the MPMF team are a second family.

I would like to thank my mother Katherine for supporting me through these years and raising me to be the man I am today. I would also like to thank my grandparents who have always been supporting of all my endeavours, especially Margie who may be the smartest non-scientist-scientist I know and Geoffry “Sticky” Steele. Who taught me how to be hands on, building little motorised boats made from Huon pine, and now I’m fixing multimillion dollar machines I have come a little way? I honestly think hanging out at lake Margret and seeing all the cool equipment contributed to my love of science.

Finally, Dr Natalie Strange, I do not have the words to describe how much I appreciate everything you have done for me. We have come an awfully long way together; your care and help has gotten me here. This thesis would not have been possible without you. Every late night and early morning in the lab. These have been the best/worst years of my life; I wish you every happiness in the world and could never repay how much you have done for me. Thank you.

To anyone else not outright mentioned, I would like to thank you. If you are reading this, thank you for looking at this work, I hope this research has helped push the boundary of knowledge.

Abstract

Neurodegenerative diseases cause significant morbidity and mortality globally, with the prevalence continuing to rise due to prolonged life expectancy. Many neurodegenerative disorders share a common pathology that involves protein misfolding, aggregation and deposition in the brain. Dietary intake of non-protein amino acids has previously been linked to such proteinopathies, with indirect evidence indicating potential misincorporation of non-protein amino acids into growing protein chains. Phenotypic and proteomic investigations could provide more direct evidence of misincorporation and further elucidate the role that non-protein amino acids may play in neurodegenerative disease. The aim of this work was to determine if non-protein amino acids incorporate into the human proteome at a level detectable by mass spectrometry, with a focus on the amino acids L-DOPA, BMAA, and azetidine 2-carboxylic acid. An enzymatic method for the conversion of tyrosine residues to L-DOPA was successfully developed, providing a basis for studying the incorporation of L-DOPA into proteins. L-DOPA incorporation into proteins was also detected following treatment of human neuronal cells *in vitro*, with quantitative proteomics revealing activation of the unfolded protein response, evidence of oxidative stress, and changes in pathways involved in neurodegenerative diseases. Meta-analysis of proteomics datasets revealed a significant effect of sample preparation on the oxidation of samples, which could potentially mask true *in vivo* oxidation. Labelling techniques and mass spectrometer resolution were also found to be important for the identification of unique peptides and modifications, including misincorporated amino acids. The treatment of human neuronal cells with BMAA *in vitro* induced proteomic changes indicating a profile of toxicity like that previously reported for glutamate-mediated excitotoxicity, but the incorporation of BMAA into proteins was not detected. Conversely, the incorporation of azetidine 2-carboxylic acid into proteins was readily detectable following *in vitro* treatment of cells, importantly in proteins involved in cell proteostasis. Azetidine 2-carboxylic acid also resulted in quantitative proteomic changes, including an increased abundance of protein folding machinery and a decreased abundance of translational machinery. The significant proteomic changes in neuronal cells following exposure to all three non-protein amino acids investigated indicated changes in pathways potentially related to neurodegeneration and neurotoxicity, indicating a potential role in such pathologies that should be further explored. This thesis also provided direct evidence that certain non-protein amino acids can be incorporated into human proteins at a level detectable by mass spectrometry, paving the way for future studies to further investigate the role of such amino acids in human disease.

Contents

Certificate of Authorship and Originality	i
List of Figures	viii
List of Tables	viii
List of publications	ix
Publications associated with this thesis.....	ix
Other works published during PhD candidature	x
Conference Proceedings	xi
Published abstracts.....	xi
Poster presentations.....	xi
Abbreviations.....	xii
Thesis organisation	xv
Chapter One: Introduction and Overview of Thesis	1
1.1 General Introduction.....	1
1.1 Non-protein amino acids and incorporation	2
1.2 The absence of the smoking gun: Proof of NPAA Incorporation	10
1.3 Aims of this thesis	11
Chapter Two: Literature Review: “Misincorporation Proteomics Technologies: A Review”	12
Chapter Overview (published manuscript)	12
Certificate of authorship and originality	13
Chapter Three: A Novel Method for Creating a Synthetic L-DOPA Proteome and <i>In Vitro</i> Evidence for Incorporation of L-DOPA into Proteins	34
Chapter Overview (published manuscript)	34
Certificate of authorship and originality	35
Chapter Four: Meta-analysis of publicly available data to identify the presence of L-DOPA in proteins	51
4.1 Introduction	51
4.2 Materials and methods	52
4.2.1 Meta-analyses of online datasets for L-DOPA incorporation	52
4.2.2 PEAKS software methodology.....	53
4.2.3 STRING DB analysis methodology	53
4.3 Results	54
4.3.1 Human draft proteome reanalysis (Brain)	54

4.3.2 Analysis of substantia nigra from Parkinson's patients' and control patients' (TMT dataset: PXD000427).....	65
4.3.3 Olfactory proteome: analysis of label-free quantitative dataset	72
4.4 Discussion.....	77
4.4.1 Human draft proteome reanalysis (Brain)	77
4.4.2 Parkinson's substantia nigra TMT dataset: PXD000427	83
4.4.3 PXD000427: Summary of dataset analysis.....	87
4.4.4 Olfactory Proteome dataset	89
4.5 Conclusions and Future Directions	91
Chapter 5 Investigation of β -Methylamino-L-alanine (BMAA) and azetidine 2-carboxylic acid (AZE) incorporation and the effects on neuronal cells <i>in vitro</i>	94
5.1 Introduction	94
5.2 Methods.....	97
5.2.1 Cell culture:	97
5.2.2 Sample processing	97
5.2.3 Gel based protein quantification	98
5.2.4 In gel digestion	98
5.2.5 Bioinformatics	98
5.3 Results.....	100
5.3.1 Overview of dataset for all conditions.....	100
5.3.2 BMAA treatment results	100
5.3.3 Azetidine treatment results	102
5.4 Discussion.....	111
5.4.1 BMAA <i>in vitro</i> treatment does not result in detectable misincorporation.....	111
5.4.2 BMAA treatment results cellular stress responses and perturbs the spliceosome.....	112
5.4.3 Azetidine 2-carboxylic acid incorporates readily into the neuronal proteome.....	114
5.5 Conclusions	119
Chapter 6: General discussion and future directions	120
6.1 Introduction	120
6.2 Misincorporation proteomics is an emerging field.....	121
6.2.1 Future directions in field of misincorporation proteomics.....	122
6.3 A method for synthesising L-DOPA positive controls and investigation of L-DOPA as a possible source of oxidative stress	124
6.3.1 Future directions in proteomic studies investigating PB-DOPA	124
6.4 Meta-analyses enable re-interrogation of <i>in vivo</i> experiments, establishing the presence of L-DOPA in human proteomes	125
6.4.1 Future directions.....	125

6.5 The NPAA azetidine 2-carboxylic acid is readily incorporated into proteomes triggering a cellular response to aberrant proteins.	127
6.5.1.1 Role in multiple sclerosis	127
6.5.1.2 Potential role for AZE in wider diseases of neurological nature.....	127
6.5.1.3 Future directions for analysis and implication of AZE incorporation	128
6.5.2 BMAA is not incorporated into the proteome at a detectable level	128
6.6 General future directions.....	129
6.6.1 Technologies that can be applied non-protein amino acid proteomics studies.....	129
6.6.2 Biological experiments that should be performed to investigate each NPAA in order to identify misincorporation	130
6.7 Concluding Remarks.....	131
Appendices.....	132
A_1: General files and installers	132
A_2: No associated data	132
A_3: Chapter 3	132
A_4: Chapter 4	132
Appendix 4_1_1 Human brain proteome Peaks project	132
Appendix 4_1_2 Human brain proteome outputs and supplementary files.....	133
Appendix 4_2_1 Substantia nigra TMT (PXD000427) Peaks project file	134
Appendix 4_2_2 Substantia nigra TMT (PXD000427) outputs and supplementary files.....	134
Appendix 4_3_1 Olfactory proteome (PXD008036) Peaks project file.....	134
Appendix 4_3_2 Olfactory proteome (PXD008036) outputs and supplementary files	134
A_5:Chapter 5	135
Appendix 5_1 Peaks project file.....	135
Appendix 5_2 Outputs and supplementary files	135
References	136

List of Figures

FIGURE 1 PUBLISHED SPECTRA OF INCORPORATION: AZE IN PLACE OF PROLINE [74].....	3
FIGURE 2: EVIDENCE OF L-DOPA CONTAINING PROTEINS.	8
FIGURE 3: HUMAN PROTEOME OXIDATION AND PB-DOPA (BRAIN TISSUE SUBSET). T.....	57
FIGURE 4: VENN DIAGRAM OF PB-DOPA AND OX-PHE ACCESSIONS (PROTEIN IDENTITIES) ATTACHED TO PEPTIDE SEQUENCES CONTAINING EACH MODIFICATION..	58
FIGURE 5: PROTEINS CONTAINING BOTH PB-DOPA AND OXIDISED PHENYLALANINE.....	60
FIGURE 6: PROTEIN'S CONTAINING PB-DOPA BASED ON UNIQUE IDENTIFIERS.	62
FIGURE 7: NETWORK ANALYSIS OF PROTEINS CONTAINING ONLY OX-PHE CONTAINING PEPTIDES, 313 IDENTITIES MATCHED OUT OF 438 SUPPLIED.	64
FIGURE 8: TUKEY BOXPLOT REPRESENTING THE QUANTITATIVE AMOUNT OF EACH OXIDATION SITE IN PD RELATIVE TO THE CONTROL.....	68
FIGURE 9: VENN DIAGRAM OF PROTEINS CONTAINING PB-DOPA AND OX-PHE FROM THE PXD000427 PD-TMT DATASET. THIS WAS CREATED USING ALL ACCESSIONS MAPPING TO ALL PEPTIDES FOR EACH RESPECTIVE MODIFICATION.	69
FIGURE 10: STRING NETWORK OF PROTEINS ANNOTATED TO CONTAIN BOTH PB-DOPA AND OX-PHE.....	70
FIGURE 11: STRING NETWORK GENERATED FROM PB-DOPA ACCESSIONS THAT WERE NOT MAPPED TO CONTAIN OX-PHE.....	71
FIGURE 12: STRING NETWORK OF PROTEINS ANNOTATED TO CONTAINING OX-PHE BY UNIQUE ACCESSION, 31 IDENTITIES MAPPED FROM 78 ACCESSIONS.....	71
FIGURE 13: BOXPLOTS OF PERCENTAGE MODIFICATION COMPARED AT THE PEPTIDE LEVEL (LEFT) AND THE RESIDUE LEVEL (RIGHT).....	72
FIGURE 14: PERCENTAGE OF MODIFIED PEPTIDES RELATIVE TO PEPTIDES CONTAINING THE AMINO ACID SITE FOR MODIFICATION.....	73
FIGURE 15: PERCENTAGE OF MODIFIED RESIDUES CONTAINING THE AMINO ACID SITE MODIFICATION COMPARED TO ALL SITES OF THAT AMINO ACID..	74
FIGURE 16: PEARSON'S CORRELATION ANALYSIS OF PARKINSON'S SAMPLE ATTRIBUTES AGAINST OXIDATION SITES BY RESIDUE (Y= PB-DOPA, M= OX-MET, F= OX=PHE)..	75
FIGURE 17: PEARSON'S CORRELATION ANALYSIS OF CONTROL SAMPLE ATTRIBUTES AGAINST OXIDATION SITES BY RESIDUE (Y= PB-DOPA, M= OX-MET, F= OX=PHE)..	76
FIGURE 18 ANALYSIS OF AZE CONTAINING PEPTIDES ACROSS BOTH CONDITIONS.....	103
FIGURE 19: STRING PHYSICAL NETWORK OF PROTEINS CONTAINING AZE.....	105
FIGURE 20: PHYSICAL PROTEIN NETWORK OF PROTEINS GREATER THAN TWO-FOLD INCREASED UPON AZE TREATMENT..	107
FIGURE 21: STRING GENERATED PHYSICAL NETWORK ON THE 220 PROTEINS OF DECREASED ABUNDANCE DUE TO AZE TREATMENT.....	108
FIGURE 22: STRING PHYSICAL NETWORK OF PROTEINS DECREASED IN ABUNDANCE DUE TO THE ADDITION OF PROLINE VERSUS AZETIDINE ALONE.....	110

List of Tables

TABLE 1: SUMMARY STATISTICS OF THE REANALYSED HUMAN BRAIN PROTEOME.....	55
TABLE 2: OVERVIEW OF DATASET PRODUCED BY REANALYSIS OF PXD000427.	65
TABLE 3: PROTEINS OF DIFFERENTIAL ABUNDANCE IN THE SUBSTANTIA NIGRA OF PARKINSON'S PATIENTS VERSUS HEALTHY AGE-MATCHED CONTROL PATIENTS.....	67
TABLE 4: PROTEINS SIGNIFICANTLY CHANGING UPON BMAA TREATMENT.	101
TABLE 5: STATISTICALLY ENRICHED DISEASE-GENE ASSOCIATIONS FROM PROTEINS CONTAINING AZE. EXTENDED TABLE MATCHES CAN BE FOUND IN APPENDIX 5_1 SUPPLEMENTARY FILE 1 AND SHEET "AZE_ENRICHMENT.DISEASES".....	106
TABLE 6: PROTEINS FOUND TO BE INCREASED IN ABUNDANCE UPON THE COTREATMENT OF PROLINE AND AZETIDINE VERSUS AZETIDINE ALONE.....	109

List of publications

Publications associated with this thesis

Steele, J.R., Italiano, C.J., Phillips, C.R., Violi, J.P., Pu, L., Rodgers, K.J. & Padula, M.P. (2021), 'Misincorporation proteomics technologies: a review', *Proteomes*, vol. 9, no. 1, p. 2.

Steele, J.R., Strange, N., Rodgers, K.J. & Padula, M.P. (2021), 'A novel method for creating a synthetic L-DOPA proteome and in vitro evidence of incorporation', *Proteomes*, vol. 9, no. 2, p. 24.

Violi, J.P., Bishop, D.P., Padula, M.P., **Steele, J.R.** & Rodgers, K.J. (2020), 'Considerations for amino acid analysis by liquid chromatography-tandem mass spectrometry: A tutorial review', *TrAC Trends in Analytical Chemistry*, p. 116018.

Quinn, A.W., Phillips, C.R., Violi, J.P., **Steele, J.R.**, Johnson, M.S., Westerhausen, M.T. & Rodgers, K.J. (2021), ' β -Methylamino-L-alanine-induced protein aggregation in vitro and protection by L-serine', *Amino Acids*, vol. 53, no. 9, pp. 1351-9.

Samardzic, K., **Steele, J.R.**, Violi, J.P., Colville, A., Mitrovic, S.M. & Rodgers, K.J. (2021), 'Toxicity and bioaccumulation of two non-protein amino acids synthesised by cyanobacteria, β -N-Methylamino-L-alanine (BMAA) and 2, 4-diaminobutyric acid (DAB), on a crop plant', *Ecotoxicology and Environmental Safety*, vol. 208, p. 111515.

Other works published during PhD candidature

Widjaja, M., Harvey, K.L., Hagemann, L., Berry, I.J., Jarocki, V.M., Raymond, B.B.A., Tacchi, J.L., Gründel, A., **Steele, J.R.** & Padula, M.P. (2017), 'Elongation factor Tu is a multifunctional and processed moonlighting protein', *Scientific Reports*, vol. 7, no. 1, pp. 1-17.

Facey, J.A., **Steele, J.R.**, Violi, J.P., Mitrovic, S.M. & Cranfield, C. (2019), 'An examination of microcystin-LR accumulation and toxicity using tethered bilayer lipid membranes (tBLMs)', *Toxicon*, vol. 158, pp. 51-6.

Jarocki, V.M., **Steele, J.R.**, Widjaja, M., Tacchi, J.L., Padula, M.P. & Djordjevic, S.P. (2019), 'Formylated N-terminal methionine is absent from the Mycoplasma hyopneumoniae proteome: Implications for translation initiation', *International Journal of Medical Microbiology*, vol. 309, no. 5, pp. 288-98.

O'Rourke, M.B., Town, S.E., Dalla, P.V., Bicknell, F., Koh Belic, N., Violi, J.P., **Steele, J.R.** & Padula, M.P. (2019), 'What is normalization? The strategies employed in top-down and bottom-up proteome analysis workflows', *Proteomes*, vol. 7, no. 3, p. 29.

Berry, I.J., Widjaja, M., Jarocki, V.M., **Steele, J.R.**, Padula, M.P. & Djordjevic, S.P. (2021), 'Protein cleavage influences surface protein presentation in Mycoplasma pneumoniae', *Scientific Reports*, vol. 11, no. 1, pp. 1-15.

Chen, H., Wang, B., Li, G., **Steele, J.R.**, Stayte, S., Vissel, B., Chan, Y.L., Yi, C., Saad, S. & Machaalani, R. (2021), 'Brain health is independently impaired by E-vaping and high-fat diet', *Brain, Behavior, and Immunity*, vol. 92, pp. 57-66.

Prakash, A., Taylor, L., Varkey, M., Hoxie, N., Mohammed, Y., Goo, Y.A., Peterman, S., Moghekar, A., Yuan, Y., Glaros, T., **Steele, J.R.**, Faridi, P., Parihari, S., Srivastava, S., Otto, J.J., Nyalwidhe, J.O., Semmes, O.J., Moran, M.F., Madugundu, A., Mun, D.G., Pandey, A., Mahoney, K.E., Shabanowitz, J., Saxena, S. & Orsburn, B.C. (2021), 'Reinspection of a Clinical Proteomics Tumor Analysis Consortium (CPTAC) dataset with cloud computing reveals abundant post-translational modifications and protein sequence variants', *Cancers*, vol. 13, no. 20, p. 5034.

Conference Proceedings

Published abstracts

Rodgers, K., Chan, S. & **Steele, J.** (2017), 'Administration of L-tyrosine with levodopa could be neuroprotective in Parkinson's disease', Journal of Neurochemistry, vol. 142, Wiley 111 River St, Hoboken 07030-5774, NJ USA, pp. 245. **(Conference article)**

Rodgers, K., **Steele, J.** & Padula, M. (2017), 'A novel approach to detect the presence of levodopa (IDOPA) in the polypeptide chains of proteins', Journal of Neurochemistry, vol. 142, Wiley 111 River St, Hoboken 07030-5774, NJ USA, pp. 164. **(Conference article)**

Chen, H., **Steele, J.**, Li, G., Chan, Y., Oliver, B., Saad, S. & Machaalani, R. (2019), 'E-vapour inhalation—How does it affect memory?', IBRO Reports, vol. 6, pp. S208-S9. **(Conference article)**

Poster presentations

2017

22nd Annual Lorne Proteomics Symposium (Lorne, Australia)

Title: Using proteomic analysis to uncover the mechanisms of non-protein amino acids attributed to neurological diseases (#37). Authors: **Joel Steele**, Matt Padula, Kenneth Rodgers. Presented a lightning talk for this abstract, the poster also won an award.

2018

23rd Annual Lorne Proteomics Symposium (Lorne, Australia)

Title: Non-protein amino acids and neurological disease: their detection in human proteins and effects. Authors: **Joel Steele**, Matt Padula, Kenneth Rodgers.

2019

18th Human Proteome Organization World Congress – HUPO (Adelaide, Australia)

Three abstracts were awarded a poster presentation:

- Proteomic mapping of chemical warfare agent exposed plasma abs# 856.
- Mapping hydroxylated tyrosine in the human brain proteome: The formation and incorporation of L-DOPA abs# 857
- The neurotoxin β -Methylamino-L-alanine and its incorporation into proteins abs# 858

Abbreviations

α -2M	Alpha-2-macroglobulin
aaRS	Aminoacyl tRNA synthetase
AD	Alzheimer's disease
AEG	N-(2-aminoethyl) glycine
ALS	Amyotrophic lateral sclerosis
ALS-PDC	Amyotrophic lateral sclerosis-Parkinson's Dementia complex
AMBIC	Ammonium bi-carbonate
AQS	6-aminoquinolyl-N-hydroxysuccinimidyl-carbate
AZE	Azetidine-2-carboxylic acid
BCA	Bicinchonic acid
BMAA	β -methylamino-L-alanine
BOAA	β -N-oxalyl- α , β -L-diaminopropionic acid
BSA	Bovine serum albumin
CDC42	Cell division control protein 42 homolog
CHOP	CCAT-enhancer-binding protein homologous protein
CID	Collisional induced dissociation
CNS	Central nervous system
CSF	Cerebral spinal fluid
Da	Dalton
DAB	L-2,4-diaminobutyric acid
DDA	Data dependent analysis
D-DOPA	D-3,4-dihydroxyphenylalanine
DENR	Density-regulated protein
DIA	Data independent analysis
DMEM	Dulbecco's Modified Eagles' Medium
DTT	Dithiothreitol
EBT	1,1'-ethylidene-bis[L-tryptophan]
EDTA	Ethylenediaminetetraacetic acid
EMS	Eosinophilia Myalgia Syndrome
ER	Endoplasmic reticulum
FDR	False discovery rate
FLD	Fluorescence detector
FL-HPLC	high-pressure liquid chromatography-fluorescence platform

GAPDH	glycerol-3-phosphate dehydrogenase
GC	Gas chromatography
GNB2	Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2
HBB	Haemoglobin
HEPES	(2-hydroxyethyl)-1-piperazine ethanesulfonic acid
HNRNPD	Heterogeneous nuclear ribonucleoprotein D0
IAA	iodoacetamide
IDA	Intelligent data Acquisition
LC	Liquid chromatography
LC-MS/MS	Liquid chromatography tandem mass spectrometry
L-DOPA	L-3,4-dihydroxyphenylalanine
LFQ	Label free quantification
LOPIT	Localisation of organelle proteins by isotope tagging
m/z	Mass-to-charge ratio
MBP	Myelin basic protein
MEM	Minimum Essential Medium
MiP	Misincorporation proteomics
MND	Motor neuron disease
MRM	Multiple reaction monitoring
mRNA	Messenger RNA
MS	Multiple sclerosis
MS/MS	Tandem mass spectrometry
NBT	Nitroblue tetrazolium
NPAA	Non-protein amino acid
OST	Oligosaccharyl transferase complex
Ox-Met	Oxidised methionine
Ox-Phe	Oxidised phenylalanine
PB-DOPA	Protein bound L-DOPA
PBS	Phosphate-buffered saline
PD	Parkinson's disease
PMI	Post mortem interval
PPIA	Peptidyl-prolyl cis-trans isomerase A
PRM	Parallel reaction monitoring
PRMT1	Protein arginine N-methyltransferase

PSM	Peptide spectral match
PTM	Post translational modification
PVDF	Polyvinylidene fluoride
ROS	Reactive oxygen species
RTS-SPS-MS3	Real time search enabled SPS-MS3
SART1	U4/U6.U5 tri-snRNP-associated protein 1
SDS	Sodium dodecyl sulphate
SDS-PAGE	Sodium dodecyl sulphate polyacrylamide gel electrophoresis
SEM	standard error of the mean
SILAC	Stable isotope labelling by amino acids in cell culture
SLE	Systemic lupus erythematosus
SNRPG	Small nuclear ribonucleoprotein G
SNRPGP15	Putative small nuclear ribonucleoprotein G-like protein 15
SPRM1	Serine/arginine repetitive matrix protein 1
SPS-MS3	synchronous precursor selection based MS3
SRM	Single reaction monitoring
SRPR	Signal recognition particle receptor subunit alpha
TAILS	N-terminal isotopic labelling of substrates
TCA	Trichloroacetic acid
TCEP	tris(2-carboxyethyl)phosphine
TDP-43	TAR DNA-binding protein 43
TMT	Tandem Mass Tags
TOF	Time of flight
tRNA	Transfer RNA
UPR	Unfolded protein response
UTC-7	7M urea, 2M thiourea, 0.1% C7BzO

Thesis organisation

The organisation of this thesis is outlined below:

- Chapter One: This introduction frames the research questions for this thesis.
- Chapter Two: Published critical review of the literature concerned with NPAAAs, the methods used to study their role and effect on an organism's proteome, and establishment of the formal pursuit of proteomic incorporation of NPAAAs, with technologies and considerations outlined to advance the field of NPAA study.
- Chapter Three: A method for the enzymatic conversion of proteomes to contain L-DOPA to create reference mass spectra for analysis of samples that potentially contain proteoforms with L-DOPA incorporated, as well as providing evidence for L-DOPAs *in vitro* toxicity, and the parallels of the toxicity to a state of neurodegeneration highlighted.
- Chapter Four: Meta-analysis of publicly available data for the presence of proteoforms/peptidoform incorporated L-DOPA to establish a baseline of L-DOPA presence in the human proteome. The draft map of the human proteome (brain subset) was analysed as a baseline for control. A Parkinson's disease TMT labelling experiment on the substantia nigra was also analysed and finally a label free LC-MS/MS dataset of the proteome of the olfactory lobes of Parkinson's sufferers.
- Chapter Five: The effect of BMAA and Azetidine 2-carboxylic acid on the neuronal proteome of SH-SY5Y cells and their incorporation.
- Chapter Six: General discussion, future directions and concluding remarks.
- Appendices
- References